{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:16:19Z","timestamp":1707524179702},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,18]]},"DOI":"10.7759\/cureus.12757","type":"journal-article","created":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T08:06:33Z","timestamp":1610957193000},"source":"Crossref","is-referenced-by-count":1,"title":["A Comparison of Disease Severity and Outcomes in COVID-19 Cases Taking Angiotensin-Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers Versus Other Antihypertensive Drugs"],"prefix":"10.7759","author":[{"given":"Muhammad","family":"Abdullah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khurshid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munaza","family":"Javed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javeid","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Waheed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Naeem","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijaz Zeeshan K","family":"Chachar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of Covid-19 in New York City","volume":"382","author":"Goyal P","year":"2020","unstructured":"Goyal P, Choi JJ, Pinheiro LC, et al.. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020, 382:2372-4. 10.1056\/NEJMc2010419","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang L","year":"2020","unstructured":"Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020, 8:e21. 10.1016\/S2213-2600(20)30116-8","journal-title":"Lancet Respir Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.016509","article-title":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?","volume":"9","author":"Sommerstein R","year":"2020","unstructured":"Sommerstein R, Kochen MM, Messerli FH, Gr\u00e4ni C. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers have a biphasic effect?. J Am Heart Assoc. 2020, 9:e016509. 10.1161\/JAHA.120.016509","journal-title":"J Am Heart Assoc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.4103\/JOD.JOD_30_20","article-title":"COVID-19, hypertension, and cardiovascular disease","volume":"11","author":"Chopra HK","year":"2020","unstructured":"Chopra HK, Kasliwal RR, Muruganathan A, Wali M, Ram CVS. COVID-19, hypertension, and cardiovascular disease. J Diabetol. 2020, 11:57-64. 10.4103\/JOD.JOD_30_20","journal-title":"J Diabetol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann M","year":"2020","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, et al.. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020, 181:271-80. 10.1016\/j.cell.2020.02.052","journal-title":"Cell"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li W","year":"2003","unstructured":"Li W, Moore MJ, Vasilieva N, et al.. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003, 426:450-4. 10.1038\/nature02145","journal-title":"Nature"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2020.1624","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","volume":"5","author":"Li J","year":"2020","unstructured":"Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020, 5:825-30. 10.1001\/jamacardio.2020.1624","journal-title":"JAMA Cardiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2006923","article-title":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","volume":"382","author":"Mancia G","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020, 382:2431-40. 10.1056\/NEJMoa2006923","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taaa041","article-title":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","volume":"27","author":"Diaz JH","year":"2020","unstructured":"Diaz JH. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19. J Travel Med. 2020, 27:taaa041. 10.1093\/jtm\/taaa041","journal-title":"J Travel Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002450","article-title":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","volume":"38","author":"Esler M","year":"2020","unstructured":"Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?. J Hypertens. 2020, 38:781-2. 10.1097\/HJH.0000000000002450","journal-title":"J Hypertens"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","volume":"111","author":"Ferrario CM","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, et al.. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005, 111:2605-10. 10.1161\/CIRCULATIONAHA.104.510461","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/path.1570","article-title":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis","volume":"203","author":"Hamming I","year":"2004","unstructured":"Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004, 203:631-7. 10.1002\/path.1570","journal-title":"J Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1042\/CS20120162","article-title":"Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions","volume":"123","author":"Burchill LJ","year":"2012","unstructured":"Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clin Sci (Lond). 2012, 123:649-58. 10.1042\/CS20120162","journal-title":"Clin Sci (Lond)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","volume":"382","author":"Vaduganathan M","year":"2020","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. N Engl J Med. 2020, 382:1653-9. 10.1056\/NEJMsr2005760","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.11301","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality","volume":"324","author":"Fosb\u00f8l EL","year":"2020","unstructured":"Fosb\u00f8l EL, Butt JH, \u00d8stergaard L, et al.. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality. JAMA. 2020, 324:168-77. 10.1001\/jama.2020.11301","journal-title":"JAMA"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007621","article-title":"Cardiovascular disease, drug therapy, and mortality in Covid-19","volume":"382","author":"Mehra MR","year":"2020","unstructured":"Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020, 382:e102. 10.1056\/NEJMoa2007621","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317393","article-title":"Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people","volume":"106","author":"Hippisley-Cox J","year":"2020","unstructured":"Hippisley-Cox J, Young D, Coupland C, et al.. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin receptor blockers: cohort study including 8.3 million people. Heart. 2020, 106:1503-11. 10.1136\/heartjnl-2020-317393","journal-title":"Heart"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-00221-6","article-title":"Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients","volume":"6","author":"Yan F","year":"2020","unstructured":"Yan F, Huang F, Xu J, et al.. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov. 2020, 6:77. 10.1038\/s41421-020-00221-6","journal-title":"Cell Discov"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/47800-a-comparison-of-disease-severity-and-outcomes-in-covid-19-cases-taking-angiotensin-converting-enzyme-inhibitorsangiotensin-receptor-blockers-versus-other-antihypertensive-drugs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:28:14Z","timestamp":1707506894000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/47800-a-comparison-of-disease-severity-and-outcomes-in-covid-19-cases-taking-angiotensin-converting-enzyme-inhibitorsangiotensin-receptor-blockers-versus-other-antihypertensive-drugs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,18]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.12757","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,18]]}}}